Skip to Content
Merck

Granulomatous hepatitis associated with glyburide.

Digestive diseases and sciences (1996-02-01)
D Saw, E Pitman, M Maung, P Savasatit, D Wasserman, C K Yeung
ABSTRACT

A wide variety of diseases and injuries can cause granulomatous hepatitis, and drug-induced granulomatous hepatitis is a well-described entity. Sulfonylurea derivatives, which are commonly used oral hypoglycemic agents in the treatment of non-insulin-dependent diabetes mellitus, have been implicated in liver disease. However, glyburide, a second-generation sulfonylurea and a potent hypoglycemic drug, is considered to have less hepatic side effects than chlorpropamide. It has been reportedly associated with cholestatic jaundice and hepatitis and with hypersensitivity angitis. A case of necrotizing granuloma has been reported. We present a second case of granulomatous hepatitis occurring in a patient who had been taking glyburide for approximately three years, and we review the literature for glyburide-associated hepatitis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glybenclamide, ≥99% (HPLC)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Glyburide, meets USP testing specifications
SKU
Pack Size
Availability
Price
Quantity
Glybenclamide, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Glibenclamide for peak identification, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Supelco
Glyburide (Glibenclamide), Pharmaceutical Secondary Standard; Certified Reference Material
SKU
Pack Size
Availability
Price
Quantity